FDA Oversight Of DTC Ads Will Be Examined By HHS Inspector General

The Inspector General will determine the effectiveness of FDA procedures for monitoring DTC ads and what actions are taken against companies with false and misleading ads, the IG’s fiscal 2005 work plan says. FDA’s handling of off-label drug promotions will also be studied.